The majority of rodent models used to evaluate analgesic drug effects rely on evoked measures of nociceptive thresholds as primary outcomes. These approaches are often time-consuming, requiring extensive habituation sessions and repeated presentations of eliciting stimuli, and are prone to false-positive outcomes due to sedation or tester subjectivity. Here, we describe the reduction of spontaneous activity by adjuvant (RSAA) model as an objective and quantifiable behavioral model of inflammatory pain that can predict the analgesic activity of a variety of agents following single-dose administration. In the RSAA model, activity was measured in nonhabituated rats using standard, photocell-based monitors. Bilateral inflammation of the knee joints by complete Freund's adjuvant (CFA) reduced the normal level of activity (horizontal locomotion and vertical rearing) by ϳ60% in a novel environment. This reduction in activity was dose-dependently reversed by ibuprofen, rofecoxib, celecoxib, piroxicam, and dexamethasone, whereas gabapentin and amitriptyline were inactive. Morphine significantly reversed the activity-suppressing effects of CFA, at 1 mg/kg s.c., but at higher doses locomotor activity progressively declined, coincident with the induction of sedation. In contrast to morphine and anti-inflammatory therapies, amphetamine did not affect vertical rearing, even though it increased horizontal locomotion. Thus, unlike standard measures of analgesia such as alteration in thermal or mechanical sensitivity, the RSAA model operationally defines analgesia as a drug-induced increase in spontaneous behavior (vertical rearing in a novel environment). We conclude that the RSAA model is valuable as an objective measure of analgesic efficacy that is not dependent on an evoked stimulus response.Due to the emotional and subjective nature of pain, the preclinical testing of novel analgesic agents has proven to be a challenging undertaking. The measurement of nociception and subsequent antinociceptive properties of compounds has traditionally been performed in assays that measure an animal's responsiveness to differing evoked nociceptive stimuli. Such assays have to be amenable to displaying either allodynia or hyperalgesia resulting from inflammatory or neuropathic pain induction, as well as detecting the ability of drugs to reverse this hypersensitivity.The most widely used analgesia assays assess mechanical and thermal sensitivity. These include mechanical/tactile allodynia measured by von Frey filaments (Chaplan et al., 1994), mechanical hyperalgesia measured by the RandallSelitto paw pressure test (Randal and Selitto, 1957), and heat hyperalgesia measured by the Hargreaves radiant heat assay (Hargreaves et al., 1988). These standard rodent hypersensitivity models may be potentially biased by rater subjectivity (e.g., von Frey test) or require exposure to a manually applied noxious stimulus (e.g., paw pressure test, radiant heat assay), and all rely on an evoked measure of sensitivity. Furthermore, although these mode...